Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Biosynex SA ( (FR:ALBIO) ) has shared an announcement.
Biosynex SA has announced a capital increase with the preferential subscription right of shareholders, targeting approximately 7.99 million euros. The capital increase aims to improve the company’s financial stability by strengthening its balance sheet and financing its working capital. This move is part of the company’s financial restructuring efforts, with significant commitments from existing shareholders and a new financial investor.
More about Biosynex SA
Biosynex SA operates in the healthcare industry, focusing on the development and distribution of rapid diagnostic tests. The company provides innovative diagnostic solutions to improve patient care and supports both healthcare professionals and consumers.
YTD Price Performance: 55.04%
Average Trading Volume: 374
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €22.76M
For an in-depth examination of ALBIO stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue